TITLE

Emtricitabine/Tenofovir Disoproxil Fumarate: A Viewpoint by Daniel Podzamczer

AUTHOR(S)
Podzamczer, Daniel
PUB. DATE
September 2004
SOURCE
Drugs;2004, Vol. 64 Issue 18, p2083
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Emtricitabine/tenofovir disoproxil fumarate combination has many advantages as a highly active antiretroviral therapy (HAART) for HIV infection. Both compounds are potent and well tolerated by patients. The compounds have been proven effective as part of different HAART regimens in clinical trials. Since both drugs are given as a daily single pill, they allow a simple HAART regimen to be administered. Available pharmacokinetic data suggest that the combination is safe. In addition, bioequivalence between the fixed combination and the two separate agents has recently been demonstrated. Large clinical trials are needed to confirm the benefits of the combination. In this setting, the fixed-dose combination will reduce the number of pills needed and improve treatment adherence.
ACCESSION #
14310027

 

Related Articles

  • Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature.  // Journal of Medical Case Reports;2011, Vol. 5 Issue 1, p1 

    The article presents a case study of a 47-year-old, Caucasian woman who developed Buffalo Hump at the time of antiretroviral therapy which includes raltegravir and unboosted atazanavir for treating Human Immunodeficiency virus (HIV)-1 infection. It informs that the diagnosis revealed that the...

  • Emtricitabine/Tenofovir Disoproxil Fumarate. Dando, Toni M.; Wagstaff, Antona J. // Drugs;2004, Vol. 64 Issue 18, p2075 

    â–´ The nucleoside analogue reverse transcriptase inhibitor (RTI) emtricitabine and the nucleotide analogue RTI tenofovir disoproxil fumarate (tenofovir DF) have each shown antiviral activity against a number of HIV clinical isolates and cell lines. â–´ HIV variants with reduced...

  • Emtricitabine/Tenofovir Disoproxil Fumarate: A Viewpoint by Anton Pozniak. Pozniak, Anton // Drugs;2004, Vol. 64 Issue 18, p2083 

    Emtricitabine/tenofovir disoproxil fumarate (tenofovir DF) is a novel antiretroviral combination therapy with many advantages. The pill burden will be only one tablet a day. Toxicity is low, there is no major issue with food requirements and the it can be generally be combined with...

  • The Observatory. HIV/AIDS.  // MLO: Medical Laboratory Observer;Jan2011, Vol. 43 Issue 1, p6 

    The article offers news briefs related to human immunodeficiency virus (HIV) infection which includes the report by Adult Industry Medical (AIM) Healthcare Foundation clinic, where the performer of porn films was tested HIV-positive, states that other adult film actors or his personal contacts...

  • Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. Pattacini, Laura; Murnane, Pamela M.; Baeten, Jared M.; Fluharty, Tayler R.; Thomas, Katherine K.; Bukusi, Elizabeth; Katabira, Elly; Mugo, Nelly; Donnell, Deborah; Lingappa, Jairam R.; Celum, Connie; Marzinke, Mark; McElrath, M. Juliana; Lund, Jennifer M. // Journal of Infectious Diseases;6/15/2015, Vol. 211 Issue 12, p1943 

    Background. Antiretroviral preexposure prophylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency virus (HIV) prevention strategy for populations at high risk of HIV acquisition. Although the primary mode of action...

  • Hope and hype.  // Network Magazine of the Canadian Women's Health Network;Winter1998/1999, Vol. 2 Issue 1, p3 

    Relates how the author decided to go on combination therapy to combat HIV-related symptoms. Author's initial refusal to take any AIDS drugs; Details of how the author reached the decision to try a combination of AIDS drugs; Author's daily medication routine; Effects of the combination therapy.

  • Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Machado, E. S.; Hofer, C. B.; Costa, T. T.; Nogueira, S. A.; Oliveira, R. H.; Abreu, T. F.; Evangelista, L. A.; Farias, I. F. A.; Mercadante, R. T. C.; Garcia, M. F. L.; Neves, R. C.; Costa, V. M.; Lambert, J. S. // Sexually Transmitted Infections;Apr2009, Vol. 85 Issue 2, p82 

    Objective: The potential adverse effects of antiretroviral drugs during pregnancy are discrepant and few studies, mostly from Europe, have provided information about pregnancy outcomes of those already on treatment at conception. The aim of this study was to investigate the impact...

  • Daclatasvir + Asunaprevir: First Global Approval. Poole, Raewyn // Drugs;Sep2014, Vol. 74 Issue 13, p1559 

    The combination of daclatasvir + asunaprevir [Daklinza + Sunvepra (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis....

  • Relationship between HIV/Highly Active Antiretroviral Therapy (HAART)—Associated Lipodystrophy Syndrome and Stavudine-Triphosphate Intracellular Levels in Patients with Stavudine-Based Antiretroviral Regimens. Domingo, Pere; Cabeza, Maria Carmen; Pruvost, Alain; Salazar, Juliana; del Mar Gutierrez, Maria; Mateo, Maria Gracia; Domingo, Joan C.; Fernandez, Irene; Villarroya, Francesc; Muñoz, Jessica; Vidal, Francesc; Baiget, Montserrat // Clinical Infectious Diseases;4/1/2010, Vol. 50 Issue 7, p1033 

    Background. The link between human immunodeficiency virus/highly active antiretroviral therapy (HAART)- associated lipodystrophy syndrome (HALS) and the use of thymidine analogues has been well established. However, to our knowledge, no relationship has been proven between intracellular levels...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics